Trial Update: Switching From Semaglutide to Tirzepatide Status Change

On October 22, 2026, the clinical trial titled "Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide" was listed as active, not recruiting. The trial, registered under identifier NCT07889453, does not have a phase designation listed in the available data. Its current status indicates that participant enrollment has closed but the study is still ongoing. No results have been posted for this trial as of the date noted. The study focuses on examining metabolic effects associated with transitioning patients from injectable semaglutide to tirzepatide, both of which are approved compounds used in metabolic health contexts. No efficacy or safety outcomes are included in this update, as none have been reported in the available record. Readers should note that this brief reflects only the trial's registration status and basic details as of the listed date. Further updates may follow as the trial progresses toward completion or as results become available on the registry. For additional background on tirzepatide, including its approved uses and general profile, readers can consult the compound overview for further context.